A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Science Advances

Martin P. Steinbuck, Lochana M. Seenappa, Aniela Jakubowski, Lisa K. McNeil, Christopher M. Haqq*, Peter C. DeMuth

The profound consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mandate urgent development of effective vaccines. Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid–modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice. »FULL ARTICLE